Trial · NCT01010061
Results by group141
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 141
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Obinutuzumab + Chlorambucil (GClb) | 31.1 | 95% Confidence Interval 26.5 to 35.6 | Months | |
| Progression-free Survival (PFS) | Chlorambucil (Clb) | 11.1 | 95% Confidence Interval 10.7 to 11.3 | Months | |
| Percentage of Participants With Progression Free Survival Events | Obinutuzumab + Chlorambucil (GClb) | 72.7 | Percentage of participants | ||
| Percentage of Participants With Progression Free Survival Events | Chlorambucil (Clb) | 90.7 | Percentage of participants | ||
| Progression Free Survival Based on Independent Review Committee (IRC) Data | Obinutuzumab + Chlorambucil (GClb) | 27.2 | 95% Confidence Interval 23.5 to 33.0 | Months | |
| Progression Free Survival Based on Independent Review Committee (IRC) Data | Chlorambucil (Clb) | 11.2 | 95% Confidence Interval 11.0 to 12.1 | Months | |
| Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data | Obinutuzumab + Chlorambucil (GClb) | 37.4 | Percentage of participants | ||
| Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data | Chlorambucil (Clb) | 76.3 | Percentage of participants | ||
| Percentage of Participants With End of Treatment Response (EOTR) | Obinutuzumab + Chlorambucil (GClb) | Complete Response (CR) | 17.2 | 95% Confidence Interval 12.7 to 22.6 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Chlorambucil (Clb) | Complete Response (CR) | 0.0 | 95% Confidence Interval 0.0 to 3.1 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Obinutuzumab + Chlorambucil (GClb) | Complete Response incomplete (CRi) | 4.2 | 95% Confidence Interval 2 to 7.6 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Chlorambucil (Clb) | Complete Response incomplete (CRi) | 0.0 | 95% Confidence Interval 0.0 to 3.1 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Obinutuzumab + Chlorambucil (GClb) | Partial Response (PR) | 48.3 | 95% Confidence Interval 41.8 to 54.9 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Chlorambucil (Clb) | Partial Response (PR) | 28.8 | 95% Confidence Interval 20.8 to 37.9 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Obinutuzumab + Chlorambucil (GClb) | Nodular Partial Response (nPR) | 7.6 | 95% Confidence Interval 4.5 to 11.7 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Chlorambucil (Clb) | Nodular Partial Response (nPR) | 2.5 | 95% Confidence Interval 0.5 to 7.3 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Obinutuzumab + Chlorambucil (GClb) | Stable Disease | 5 | 95% Confidence Interval 2.6 to 8.6 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Chlorambucil (Clb) | Stable Disease | 22.9 | 95% Confidence Interval 15.7 to 31.5 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Obinutuzumab + Chlorambucil (GClb) | Progressive Disease | 4.2 | 95% Confidence Interval 2.0 to 7.6 | Percentage of participants |
| Percentage of Participants With End of Treatment Response (EOTR) | Chlorambucil (Clb) | Progressive Disease | 28.8 | 95% Confidence Interval 20.8 to 37.9 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01010061/results